Successful Treatment of Carbimazole-Induced Agranulocytosis and Severe Sepsis with Granulocyte Macrophage Colony Stimulating Factor

Delannoy A. , Gehenot M. Colony stimulating factor and drug induced agranulocytosis. Ann Intern Med 1989; 110: 942–943.

Palmblad J. , Jonson B. , Kanerud L. Treatment of drug-induced agranulocytosis with recombinant GM-CSF. J Intern Med 1990; 228: 537–539.

Meletis J. , Vavourakis S. , Andreopoulos T. Recovery of carbimazole-induced agranulocytosis following recombinant granulocyte-macrophage colony stimulating factor (rh GM-CSF) administration. Haematologica 1993; 78: 329–331.

Nielsen H. Recominant human granulocyte colony-stimulating factor (rh G-CSF; filgastim) treatment of clazapine induced agranulocytosis. J Intern Med 1993; 234: 529–531.

Balkin M.S. , Buchholtz M. , Ortiz J. Propythiouracil (PTU) induced agranulocytosis treated with recombinant human granulocyte stimulating factor. Thyroid 1993; 3: 305–309.

Chia H.M. , Kalra L. , Lakhani A.K. Filgastim for low dose captopril induced agranulocytosis. [Letter]. Lancet 1993; 342: 304.

Members of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidelines for use of innovative therapies in sepsis. Crit Care Med 1992; 20: 862–874.

Strom B.L. , Carson J.L. , Schinnar E.S. , Shaw M. Descriptive epidemiology of agranulocytosis. Arch Intern Med 1992; 152: 1475–1480.

International Agranulocytosis and Aplastic Anemia Study Group; Risk of agranulocytosis and aplastic anemia in relation to the use of antithyroid drugs. Br Med J 1988; 297: 262–265.

Li K-L , Huang H-S , Wang P-W Agranulocytosis associated with Anti-thyroid Drug in Patients with Graves’ Thyrotoxicosis—Report of 11 Cases. Chang Gung Med J 1991; 14: 168–173.

Broxmeyer H.E. , Williams D.E. The production of myeloid cells and their regulation during health and disease. Crit Rev Oncol Haematol 1988; 8: 173–226.

Johnson M.H. , Gordon P.W. , Fitzgerald F.T. Stratification of prognosis in granulocytic patients with haematological malignancies using APACHE II severity illness score. Crit Care Med 1986; 14: 693–697.

Knaus W.A. , Draper E.A. , Wagner D.P. , Zimmerman J.E. APACHE II: A severity of disease classification system. Crit Care Med 1985; 13: 818–829.

Liescher G.J. , Burgess A.W. Granulocyte colony stimulating factor and granulocyte-macrophage stimulating factor. (Part 1). N Engl J Med 1992; 327: 28–35.

Fukata S. , Murakami Y. , Kuma K. , Sakane S. , Ohsawa N. , Sugawara M. G-CSF levels during spontaneous recovery from drug induced agranulocytosis. Lancet 1993; 342: 1495.

Cebon J. , Layton J.E. , Maher D. , Morstyn G. Endogenous haemopoietic growth factors in neutropenia and infection. Br J Haematol 1994; 86: 265–274.

Gennari R. , Alexander J.W. , Gianotti L. , Eaves-Pyles T. , Hartmann S. Granulocyte-macrophage colony stimulating factor improves survival in two models of gut derived sepsis by improving gut barrier function and modulating bacterial clearance. Ann Surg 1994; 220: 68–76.

Bodey G.P. , Anaissie E. , Gutterman J. , Vadhan-Raj S. Role of granulocyte-macrophage colony stimulating factor as adjunctive therapy for fungal infection in patients with cancer. Clin Infect Dis 1993; 17: 705–707.